We Are the Frontier

Alnylam Commercial Chief Exits Amid Sales Reset

The departure comes as the company's Amvuttra sales reset weighs on its stock, with no successor named yet.

Updated on Nov. 5, 2026 in Tech

Alnylam Commercial Chief Exits Amid Sales Reset

Alnylam Pharmaceuticals said Chief Commercial Officer Tolga Tanguler is leaving the company, with no reason given, in a release that also authorized a $1 billion share repurchase program. The departure is a personnel change; it is not a product or research development.

Why it matters

The exit comes after Alnylam cut its full-year guidance when sales of its approved drug Amvuttra disappointed, and its stock has fallen sharply this year. Leadership turnover in the commercial function during a revenue reset is a signal investors and partners will watch closely.

Amvuttra was first approved in 2022 for polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults and expanded in 2025 to certain patients with transthyretin-mediated amyloidosis with cardiomyopathy. Its third-quarter sales of $1.13 billion are the figure against which the company's guidance cut and recent stock declines are measured.

The players

Alnylam Pharmaceuticals

A Cambridge, Massachusetts-based RNA interference drug developer whose commercial portfolio is led by Amvuttra for transthyretin amyloidosis.

Tolga Tanguler

Alnylam's departing Chief Commercial Officer, who is leaving the company with no reason given.

William Blair

An investment bank whose analyst said it is difficult to assess Alnylam's near-term 2027 revenue estimates.

The details

Alnylam's commercial team is responsible for selling its approved medicines, so the chief commercial role sits at the point where launch forecasts meet real prescriber demand. The company cut guidance after Amvuttra sales fell short of expectations, which pressured the share price across two earnings cycles. The buyback authorization is a capital-return move that can support the share price while operating results are reset.

Timeline

  1. July 2026: Stock fell as much as 29% after second-quarter earnings and a lowered forecast.

  2. October 29, 2026: Third-quarter earnings showed Amvuttra sales in line, but the stock fell 20%.

  3. November 5, 2026: Tanguler's departure and the $1 billion buyback were announced.

The Tech Race

Amvuttra's commercial trajectory since its 2022 approval is the benchmark against which Alnylam's guidance and stock performance are now judged. The company's ability to rebuild sales momentum will determine whether its RNA-based platform can keep pace with competing approaches to the same disease area.

Patients and prescribers using Amvuttra are not affected by this personnel change, and no change to the product's approved indications has been reported. For investors and partners, the near-term outlook is harder to read, since analysts say 2027 revenue estimates are difficult to assess.

The takeaway

The key trajectory signal is whether Amvuttra's sales can recover enough to rebuild guidance, since the buyback alone does not change product revenue. Watch for the company's announcement naming its next Chief Commercialization Officer and the next quarterly earnings report for evidence on Amvuttra's sales trend.

What happens next

Alnylam says it will provide an update on the selection of its next Chief Commercialization Officer in due course, and a named successor would be the next concrete marker of the commercial leadership plan.

Further reading

For more on the companies shaping the field, see the Biotech coverage in Massachusetts.

Source note: This article includes information reported by FiercePharma.